Twin Tree Management LP Increases Stock Position in Glaukos Corporation $GKOS

Key Points

• Twin Tree Management LP increased its stake in Glaukos Corporation by 119.9%, acquiring an additional 9,827 shares, which brings their total holdings to $1,862,000 as of the latest SEC filing.
• Several institutional investors, including Wellington Management Group and AllianceBernstein, have also increased their positions in Glaukos, with 99.04% of the stock owned by hedge funds and institutional investors.
• Glaukos reported a revenue increase of 29.7% year-over-year to $124.12 million, surpassing analyst estimates, and has provided FY 2025 earnings guidance projecting negative earnings per share of -1.08.

Twin Tree Management LP boosted its stake in Glaukos Corporation (NYSE:GKOS - Free Report) by 119.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,026 shares of the medical instruments supplier's stock after acquiring an additional 9,827 shares during the period. Twin Tree Management LP's holdings in Glaukos were worth $1,862,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Wellington Management Group LLP lifted its position in Glaukos by 6.1% in the first quarter. Wellington Management Group LLP now owns 2,290,790 shares of the medical instruments supplier's stock valued at $225,460,000 after acquiring an additional 131,251 shares during the last quarter. Alliancebernstein L.P. lifted its position in Glaukos by 56.5% in the first quarter. Alliancebernstein L.P. now owns 1,277,539 shares of the medical instruments supplier's stock valued at $125,735,000 after acquiring an additional 461,386 shares during the last quarter. Primecap Management Co. CA lifted its position in Glaukos by 0.3% in the first quarter. Primecap Management Co. CA now owns 1,218,475 shares of the medical instruments supplier's stock valued at $119,922,000 after acquiring an additional 4,150 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in Glaukos by 34.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier's stock valued at $106,705,000 after acquiring an additional 277,033 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its position in Glaukos by 18.7% in the first quarter. Driehaus Capital Management LLC now owns 973,625 shares of the medical instruments supplier's stock valued at $95,824,000 after acquiring an additional 153,502 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GKOS. Truist Financial reduced their target price on shares of Glaukos from $126.00 to $120.00 and set a "buy" rating for the company in a report on Monday, September 22nd. William Blair raised shares of Glaukos to a "strong-buy" rating in a report on Thursday, July 31st. Mizuho set a $130.00 target price on shares of Glaukos in a report on Thursday, July 31st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Glaukos in a report on Wednesday, October 8th. Finally, BTIG Research reduced their target price on shares of Glaukos from $118.00 to $104.00 and set a "buy" rating for the company in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $116.92.

Glaukos Trading Down 0.3%

Shares of Glaukos stock opened at $85.34 on Friday. Glaukos Corporation has a 52-week low of $77.10 and a 52-week high of $163.71. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. The company's 50-day simple moving average is $87.69 and its 200-day simple moving average is $92.29. The firm has a market cap of $4.89 billion, a price-to-earnings ratio of -51.72 and a beta of 0.76.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. During the same period in the prior year, the business posted ($0.52) earnings per share. The firm's revenue for the quarter was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.